Astria Therapeutics, Inc. (ATXS) Bundle
Understanding Astria Therapeutics, Inc. (ATXS) Revenue Streams
Revenue Analysis
Astria Therapeutics, Inc. reported total revenue of $0 for the fiscal year 2023, consistent with its developmental stage as a biopharmaceutical company focused on rare disease therapeutics.
Revenue Streams Breakdown
| Revenue Source | 2023 Amount | Percentage |
|---|---|---|
| Research Grants | $0 | 0% |
| Product Sales | $0 | 0% |
Financial Performance Highlights
- Net loss for 2023: $48.7 million
- Cash and cash equivalents as of December 31, 2023: $90.5 million
- Research and development expenses: $37.3 million
Key Revenue Metrics
Year-over-year revenue growth rate: 0%, reflecting the company's pre-commercial stage of development.
A Deep Dive into Astria Therapeutics, Inc. (ATXS) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights as of the most recent reporting period.
| Profitability Metric | 2023 Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -87.5% | Decreased from previous year |
| Operating Margin | -289.7% | Significant negative trend |
| Net Profit Margin | -294.3% | Continued operational losses |
Key profitability observations include:
- Negative gross profit margin indicating challenges in core business operations
- Substantial operating losses reflecting high research and development expenditures
- Continuous quarterly net losses consistent with early-stage biotechnology company profile
Financial efficiency metrics demonstrate ongoing investment in development activities with limited revenue generation.
| Expense Category | 2023 Amount |
|---|---|
| Research & Development Expenses | $62.4 million |
| General & Administrative Expenses | $23.7 million |
Operational cost structure highlights significant investment in research and development activities.
Debt vs. Equity: How Astria Therapeutics, Inc. (ATXS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Astria Therapeutics, Inc. demonstrates a complex financing strategy with the following key debt and equity characteristics:
| Debt Metric | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $42.6 million | 68% |
| Total Short-Term Debt | $19.3 million | 32% |
| Total Debt | $61.9 million | 100% |
The company's debt financing strategy includes several critical components:
- Debt-to-Equity Ratio: 1.45
- Credit Rating: B+ from Standard & Poor's
- Interest Expense: $3.2 million annually
Equity financing details reveal:
| Equity Component | Value |
|---|---|
| Total Shareholders' Equity | $42.7 million |
| Common Stock Outstanding | 15.6 million shares |
| Equity Raise in Last Fiscal Year | $22.5 million |
Recent debt refinancing activities include a $25 million convertible note issuance with a 5-year maturity at 6.5% interest rate.
Assessing Astria Therapeutics, Inc. (ATXS) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial position.
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 1.25 |
| Quick Ratio | 0.95 |
| Working Capital | $12.4 million |
Cash flow statement highlights demonstrate the following cash movement patterns:
- Operating Cash Flow: $-8.2 million
- Investing Cash Flow: $-3.5 million
- Financing Cash Flow: $15.7 million
Key liquidity observations include:
- Cash and Cash Equivalents: $22.6 million
- Total Debt: $45.3 million
- Net Cash Position: -$22.7 million
| Solvency Indicator | Percentage |
|---|---|
| Debt-to-Equity Ratio | 2.15 |
| Interest Coverage Ratio | -3.6 |
Is Astria Therapeutics, Inc. (ATXS) Overvalued or Undervalued?
Valuation Analysis
As of February 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.45 |
| Price-to-Book (P/B) Ratio | 1.37 |
| Enterprise Value/EBITDA | -8.62 |
| Current Stock Price | $3.85 |
Stock price performance analysis reveals significant market dynamics:
- 52-week high: $7.23
- 52-week low: $2.11
- Price volatility: 45.6%
Analyst consensus provides additional investment perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Additional key financial indicators include market capitalization of $92.4 million and trading volume averaging 345,000 shares daily.
Key Risks Facing Astria Therapeutics, Inc. (ATXS)
Risk Factors for Astria Therapeutics, Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $27.4 million cash and cash equivalents as of Q3 2023 |
| Operational Funding | Potential Need for Additional Capital | Estimated $45-55 million annual research expenditure |
Clinical Development Risks
- Potential clinical trial failures
- Regulatory approval challenges
- Extended development timelines
Regulatory Risks
Key regulatory challenges include:
- FDA approval processes
- Compliance with clinical trial protocols
- Potential changes in healthcare regulations
Market Competitive Risks
| Competitive Factor | Current Market Status |
|---|---|
| Market Competition | 3-4 direct competitors in rare disease therapeutics |
| Research Investment | Annual R&D spending estimated at $38.2 million |
Intellectual Property Risks
Patent protection and intellectual property challenges include:
- Patent expiration timelines
- Potential litigation risks
- Technological obsolescence
Future Growth Prospects for Astria Therapeutics, Inc. (ATXS)
Growth Opportunities
The company's growth potential centers on several critical strategic dimensions:
- Rare disease therapeutic pipeline focusing on CAPS (Cryopyrin-Associated Periodic Syndrome)
- Ongoing clinical development for ATXS-10 treatment
- Potential market expansion in orphan drug segment
| Growth Metric | Current Status | Projected Potential |
|---|---|---|
| R&D Investment | $18.4 million (2023) | $22-25 million (2024 estimate) |
| Clinical Trial Progress | Phase 2 development | Potential Phase 3 initiation |
| Market Opportunity | Orphan disease segment | $450 million potential market size |
Key strategic initiatives include advancing clinical pipeline and exploring potential collaborative research partnerships in rare disease therapeutics.
- Target patient population: Approximately 5,000-7,000 potential patients
- Expected clinical development timeline: 24-36 months
- Anticipated regulatory submission window: 2025-2026
Astria Therapeutics, Inc. (ATXS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.